MX2024002684A - Metodos para la prevencion y tratamiento de sinucleinopatias. - Google Patents

Metodos para la prevencion y tratamiento de sinucleinopatias.

Info

Publication number
MX2024002684A
MX2024002684A MX2024002684A MX2024002684A MX2024002684A MX 2024002684 A MX2024002684 A MX 2024002684A MX 2024002684 A MX2024002684 A MX 2024002684A MX 2024002684 A MX2024002684 A MX 2024002684A MX 2024002684 A MX2024002684 A MX 2024002684A
Authority
MX
Mexico
Prior art keywords
synucleinopathies
methods
prevention
treatment
compositions
Prior art date
Application number
MX2024002684A
Other languages
English (en)
Spanish (es)
Inventor
Jean - Cosme Dodart
Original Assignee
Vaxxinity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxxinity Inc filed Critical Vaxxinity Inc
Publication of MX2024002684A publication Critical patent/MX2024002684A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024002684A 2021-09-01 2022-09-01 Metodos para la prevencion y tratamiento de sinucleinopatias. MX2024002684A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163239505P 2021-09-01 2021-09-01
PCT/US2022/075836 WO2023034914A2 (en) 2021-09-01 2022-09-01 Methods for the prevention and treatment of synucleinopathies

Publications (1)

Publication Number Publication Date
MX2024002684A true MX2024002684A (es) 2024-05-16

Family

ID=85413127

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024002684A MX2024002684A (es) 2021-09-01 2022-09-01 Metodos para la prevencion y tratamiento de sinucleinopatias.

Country Status (10)

Country Link
US (1) US20240358806A1 (https=)
EP (1) EP4395894A4 (https=)
JP (1) JP2024534901A (https=)
KR (1) KR20240055785A (https=)
CN (1) CN118119403A (https=)
AU (1) AU2022337284A1 (https=)
CA (1) CA3230300A1 (https=)
MX (1) MX2024002684A (https=)
TW (1) TW202323275A (https=)
WO (1) WO2023034914A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137102A1 (en) * 2023-12-18 2025-06-26 Vaxxinity, Inc. Peptide immunogen compositions and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
EP1572894B1 (en) * 2001-11-21 2016-04-13 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto
US8697082B2 (en) * 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
GB201512203D0 (en) * 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
EP3638298A4 (en) * 2017-06-16 2021-05-05 United Neuroscience PEPTIDE IMMUNOGENS FROM THE C-TERMINAL END OF ALPHA-SYNUCLEIN-PROTEIN AND FORMULATIONS THEREOF FOR THE TREATMENT OF SYNUCLEINOPATHIA

Also Published As

Publication number Publication date
US20240358806A1 (en) 2024-10-31
TW202323275A (zh) 2023-06-16
WO2023034914A2 (en) 2023-03-09
CN118119403A (zh) 2024-05-31
EP4395894A2 (en) 2024-07-10
JP2024534901A (ja) 2024-09-26
AU2022337284A1 (en) 2024-03-21
EP4395894A4 (en) 2025-08-06
CA3230300A1 (en) 2023-03-09
KR20240055785A (ko) 2024-04-29
WO2023034914A3 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
MX2023012245A (es) Compuestos, composiciones y metodos para el tratamiento del cancer.
MY206478A (en) Inhibitors of sarm1
ZA202301801B (en) Inhibitors of sarm1
MX2024001243A (es) Composiciones y metodos para el tratamiento de melanoma.
CA227900S (en) Skin treatment equipment
MX2021011488A (es) Compuestos y usos de estos.
MX2021003903A (es) Terapia combinada para el melanoma.
MX2023015021A (es) Mimeticos de hepcidina para el tratamiento de la hemocromatosis hereditaria.
MX2024004993A (es) Agentes degradantes de la proteina tirosina cinasa 2 (tyk2) y usos de los mismos.
SA522431538B1 (ar) طُرق وتركيبات لعلاج تساقط الشعر
MX2020011344A (es) Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
MX2022010944A (es) Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos.
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection
MX2021004819A (es) Composiciones y metodos para tratar lesiones cerebrales.
PH12022550118A1 (en) Enzyme inhibitors
EP4225923A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING AND/OR TREATING COVID-19
PH12022550045A1 (en) Plasma kallikrein inhibitors
IL312583A (en) A preparation for the treatment and prevention of COVID-19
MX2024002684A (es) Metodos para la prevencion y tratamiento de sinucleinopatias.
PH12021552499A1 (en) Methods for the treatment of beta-thalassemia
MX2025004758A (es) Compuestos y su uso para el tratamiento de hemoglobinopatias
MX2023004881A (es) Inhibidores de pde9 para el tratamiento de insuficiencia cardíaca.
MX2025001279A (es) Aril-triazolilo y antagonistas gpr84 relacionados y usos de estos
WO2020185651A3 (en) Compositions and methods for treating huntington's disease
MX2022013883A (es) Compuestos de metiltioninio para uso en el tratamiento de covid-19.